Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Азитромицин в лечении инфекций дыхательных путей
Кароли Н.А., Ребров А.П. Азитромицин в лечении инфекций дыхательных путей. Справочник поликлинического врача. 2017; 3: 49–53.
________________________________________________
Karoli N.A., Rebrov A.P. Azithromycin in the treatment of respiratory infections. Handbook for Practitioners Doctors. 2017; 3: 49–53.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье рассмотрены роль и значимость антибактериальных препаратов группы макролидов, и в частности азитромицина, в лечении инфекционно-воспалительных заболеваний дыхательных путей.
Ключевые слова: лечение заболеваний органов дыхания, ХОБЛ, бронхит, пневмония, макролиды, азитромицин.
Ключевые слова: лечение заболеваний органов дыхания, ХОБЛ, бронхит, пневмония, макролиды, азитромицин.
________________________________________________
The role and significance of antibacterial drugs of macrolide group, and in particular azithromycin, in the treatment of infectious and inflammatory respiratory diseases are considered in the article.
Key words: treatment of respiratory diseases, COPD, bronchitis, pneumonia, macrolides, azithromycin.
Полный текст
Список литературы
1. Yamaya M, Azuma A, Takizawa H et al. Macrolide effects on the prevention of COPD exacerbations. Eur Respir J 2012; 40: 485–94.
2. Min J, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators of Inflammation. 2012: Mediators Inflamm 2012: 649570. Published online 2012 June 6. DOI: 10.1155/2012/649570
3. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Intern J of COPD 2008; 3 (3): 331–50.
4. Лукьянов С. В. Клиническая фармакология макролидов. Consilium Medicum. 2004; 6 (10): 769–73. / Luk'ianov S. V. Klinicheskaia farmakologiia makrolidov. Consilium Medicum. 2004; 6 (10): 769–73. [in Russian]
5. Mammen MJ, Sethi S. Macrolide therapy for the prevention of acute exacerbations in chronic obstructive pulmonary disease. Pol Arch Med Wewn 2012; 122: 54–9.
6. Лукьянов С.В. Макролиды в терапии внебольничных инфекций дыхательных путей. Consilium Medicum. Болезни органов дыхания (Прил.). 2005; 1: 3–7. / Luk'ianov S.V. Makrolidy v terapii vnebol'nichnykh infektsii dykhatel'nykh putei. Consilium Medicum. Respiratory organs diseases. (Suppl.). 2005; 1: 3–7. [in Russian]
7. Amsden G. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55 (1): 10–21.
8. Blasi F, Damato S, Cosentini R et al. Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax 2002; 57: 672–6.
9. Muto C, Liu P, Chiba K et al. Pharmacokinetic-pharmacodynamic analysis of azithromycin extended release in Japanese patients with common respiratory tract infectious disease. J Antimicrob Chemother 2011; 66: 165–74.
10. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global Strategy for Diagnosis, Management and Prevention of COPD. 2016: 111.
11. Kim N, Leeper KV Jr. Epidemiology of chronic bronchitis and acute infective exacerbations of chronic bronchitis. Semin Respir Crit Care Med 2000; 21 (2): 73–8.
12. Rosell A, Monso E, Soler N et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005; 165: 891–7.
13. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. ERJ 2007; 29: 1224–38.
14. Bach PB, Brown C, Gelfand SE et al. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001; 134: 600–20.
15. McCrory DC, Brown C, Gelfand SE et al. Management of acute exacerbations of COPD. A summary and appraisal of published evidence. Chest 2001; 119: 1190–209.
16. Allegra L, Blasi F, de Bernardi B et al. Antibiotic treatment and baseline severity or disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study. Pulm Pharmacol Therapeut 2001; 14: 149–55.
17. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005; 127: 2231–6.
18. Wilson R. Treatment of COPD exacerbations: antibiotics. Eur Respir Rev 2005; 14: 32–8.
19. Miravitlles M, D'Urzo A, Singh D, Koblizek V. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respir Res 2016; 17 (1): 112.
20. Contopoulos-Ioannidis DJ, Ioannidis JPA, Chew P, Law J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 2001; 48: 691–703.
21. Schouenborg P, Gerdes N, Rasmussen HH et al. Azithromycin versus Pivampicillin in the treatment of acute exacerbations of chronic bronchitis: a single-blind, double-dummy, multicentre study. J Inter Med Res 2000; 28: 101–10.
22. Дворецкий Л.И. Азитромицин в лечении инфекций дыхательных путей. Позиции сохраняются. РМЖ. 2004; 2: 83–7. / Dvoretskii L.I. Azitromitsin v lechenii infektsii dykhatel'nykh putei. Pozitsii sokhraniaiutsia. RMZh. 2004; 2: 83–7. [in Russian]
23. Утешев Д.Б., Крылов И.А., Буюклинская О.В. Азитромицин: респираторная специфика и уникальность. Лечебное дело. 2008; 1: 15–8. / Uteshev D.B., Krylov I.A., Buiuklinskaia O.V. Azitromitsin: respiratornaia spetsifika i unikal'nost'. Lechebnoe delo. 2008; 1: 15–8. [in Russian]
24. Моисеев С.В. Азитромицин в лечении внебольничной пневмонии. Клин. фармакология и терапия. 2006: 15 (2). / Moiseev S.V. Azitromitsin v lechenii vnebol'nichnoi pnevmonii. Klin. farmakologiia i terapiia. 2006: 15 (2). [in Russian]
25. Фомина И.П., Ушкалова Е.А. Применение азитромицина для лечения внебольничных пневмоний у взрослых и детей.Фарматека. 2002; 11: 3-4. / Fomina I.P., Ushkalova E.A. Primenenie azitromitsina dlia lecheniia vnebol'nichnykh pnevmonii u vzroslykh i detei. Farmateka. 2002; 11: 3-4. [in Russian]
26. Синопальников А.И., Зайцев А.А. Азитромцин: ступенчатая терапия госпитализированных больных внебольничной пневмонией (клинико-экономические сопоставления). Consilium Medicum. 2011; 13 (11): 10–4. / Sinopal'nikov A.I., Zaitsev A.A. Azitromtsin: stupenchataia terapiia gospitalizirovannykh bol'nykh vnebol'nichnoi pnevmoniei (kliniko-ekonomicheskie sopostavleniia). Consilium Medicum. 2011; 13 (11): 10–4. [in Russian]
27. Asadi L, Sligl W, Eurich D. Macrolide-Based Regimens and Mortality in Hospitalized Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Clin Infect Dis 2012; 55 (3): 371–80.
28. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Пособие для врачей. М., 2010: 54. / Vnebol'nichnaia pnevmoniia u vzroslykh: prakticheskie rekomendatsii po diagnostike, lecheniiu i profilaktike. Posobie dlia vrachei. M., 2010: 54. [in Russian]
29. Клинические рекомендации по диагностике, лечению и профилактике тяжелой внебольничной пневмонии у взрослых. Consilium Medicum. 2015; 17 (3): 8–37. / Klinicheskie rekomendatsii po diagnostike, lecheniiu i profilaktike tiazheloi vnebol'nichnoi pnevmonii u vzroslykh. Consilium Medicum. 2015; 17 (3): 8–37. [in Russian]
30. Шмелев Е.И. Острый бронхит. Атмосфера. Пульмонология и аллергология. 2004; 3: 3–7. / Shmelev E.I. Ostryi bronkhit. Atmosfera. Pul'monologiia i allergologiia. 2004; 3: 3–7. [in Russian]
31. Лещенко И.В. Острый бронхит: современные проблемы диагностики и лечения. Медицинский совет. 2013; 3: 25–8. / Leshchenko I.V. Ostryi bronkhit: sovremennye problemy diagnostiki i lecheniia. Meditsinskii sovet. 2013; 3: 25–8. [in Russian]
2. Min J, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators of Inflammation. 2012: Mediators Inflamm 2012: 649570. Published online 2012 June 6. DOI: 10.1155/2012/649570
3. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Intern J of COPD 2008; 3 (3): 331–50.
4. Лукьянов С. В. Клиническая фармакология макролидов. Consilium Medicum. 2004; 6 (10): 769–73. / Luk'ianov S. V. Klinicheskaia farmakologiia makrolidov. Consilium Medicum. 2004; 6 (10): 769–73. [in Russian]
5. Mammen MJ, Sethi S. Macrolide therapy for the prevention of acute exacerbations in chronic obstructive pulmonary disease. Pol Arch Med Wewn 2012; 122: 54–9.
6. Лукьянов С.В. Макролиды в терапии внебольничных инфекций дыхательных путей. Consilium Medicum. Болезни органов дыхания (Прил.). 2005; 1: 3–7. / Luk'ianov S.V. Makrolidy v terapii vnebol'nichnykh infektsii dykhatel'nykh putei. Consilium Medicum. Respiratory organs diseases. (Suppl.). 2005; 1: 3–7. [in Russian]
7. Amsden G. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55 (1): 10–21.
8. Blasi F, Damato S, Cosentini R et al. Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax 2002; 57: 672–6.
9. Muto C, Liu P, Chiba K et al. Pharmacokinetic-pharmacodynamic analysis of azithromycin extended release in Japanese patients with common respiratory tract infectious disease. J Antimicrob Chemother 2011; 66: 165–74.
10. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global Strategy for Diagnosis, Management and Prevention of COPD. 2016: 111.
11. Kim N, Leeper KV Jr. Epidemiology of chronic bronchitis and acute infective exacerbations of chronic bronchitis. Semin Respir Crit Care Med 2000; 21 (2): 73–8.
12. Rosell A, Monso E, Soler N et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005; 165: 891–7.
13. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. ERJ 2007; 29: 1224–38.
14. Bach PB, Brown C, Gelfand SE et al. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001; 134: 600–20.
15. McCrory DC, Brown C, Gelfand SE et al. Management of acute exacerbations of COPD. A summary and appraisal of published evidence. Chest 2001; 119: 1190–209.
16. Allegra L, Blasi F, de Bernardi B et al. Antibiotic treatment and baseline severity or disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study. Pulm Pharmacol Therapeut 2001; 14: 149–55.
17. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005; 127: 2231–6.
18. Wilson R. Treatment of COPD exacerbations: antibiotics. Eur Respir Rev 2005; 14: 32–8.
19. Miravitlles M, D'Urzo A, Singh D, Koblizek V. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respir Res 2016; 17 (1): 112.
20. Contopoulos-Ioannidis DJ, Ioannidis JPA, Chew P, Law J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 2001; 48: 691–703.
21. Schouenborg P, Gerdes N, Rasmussen HH et al. Azithromycin versus Pivampicillin in the treatment of acute exacerbations of chronic bronchitis: a single-blind, double-dummy, multicentre study. J Inter Med Res 2000; 28: 101–10.
22. Дворецкий Л.И. Азитромицин в лечении инфекций дыхательных путей. Позиции сохраняются. РМЖ. 2004; 2: 83–7. / Dvoretskii L.I. Azitromitsin v lechenii infektsii dykhatel'nykh putei. Pozitsii sokhraniaiutsia. RMZh. 2004; 2: 83–7. [in Russian]
23. Утешев Д.Б., Крылов И.А., Буюклинская О.В. Азитромицин: респираторная специфика и уникальность. Лечебное дело. 2008; 1: 15–8. / Uteshev D.B., Krylov I.A., Buiuklinskaia O.V. Azitromitsin: respiratornaia spetsifika i unikal'nost'. Lechebnoe delo. 2008; 1: 15–8. [in Russian]
24. Моисеев С.В. Азитромицин в лечении внебольничной пневмонии. Клин. фармакология и терапия. 2006: 15 (2). / Moiseev S.V. Azitromitsin v lechenii vnebol'nichnoi pnevmonii. Klin. farmakologiia i terapiia. 2006: 15 (2). [in Russian]
25. Фомина И.П., Ушкалова Е.А. Применение азитромицина для лечения внебольничных пневмоний у взрослых и детей.Фарматека. 2002; 11: 3-4. / Fomina I.P., Ushkalova E.A. Primenenie azitromitsina dlia lecheniia vnebol'nichnykh pnevmonii u vzroslykh i detei. Farmateka. 2002; 11: 3-4. [in Russian]
26. Синопальников А.И., Зайцев А.А. Азитромцин: ступенчатая терапия госпитализированных больных внебольничной пневмонией (клинико-экономические сопоставления). Consilium Medicum. 2011; 13 (11): 10–4. / Sinopal'nikov A.I., Zaitsev A.A. Azitromtsin: stupenchataia terapiia gospitalizirovannykh bol'nykh vnebol'nichnoi pnevmoniei (kliniko-ekonomicheskie sopostavleniia). Consilium Medicum. 2011; 13 (11): 10–4. [in Russian]
27. Asadi L, Sligl W, Eurich D. Macrolide-Based Regimens and Mortality in Hospitalized Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Clin Infect Dis 2012; 55 (3): 371–80.
28. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Пособие для врачей. М., 2010: 54. / Vnebol'nichnaia pnevmoniia u vzroslykh: prakticheskie rekomendatsii po diagnostike, lecheniiu i profilaktike. Posobie dlia vrachei. M., 2010: 54. [in Russian]
29. Клинические рекомендации по диагностике, лечению и профилактике тяжелой внебольничной пневмонии у взрослых. Consilium Medicum. 2015; 17 (3): 8–37. / Klinicheskie rekomendatsii po diagnostike, lecheniiu i profilaktike tiazheloi vnebol'nichnoi pnevmonii u vzroslykh. Consilium Medicum. 2015; 17 (3): 8–37. [in Russian]
30. Шмелев Е.И. Острый бронхит. Атмосфера. Пульмонология и аллергология. 2004; 3: 3–7. / Shmelev E.I. Ostryi bronkhit. Atmosfera. Pul'monologiia i allergologiia. 2004; 3: 3–7. [in Russian]
31. Лещенко И.В. Острый бронхит: современные проблемы диагностики и лечения. Медицинский совет. 2013; 3: 25–8. / Leshchenko I.V. Ostryi bronkhit: sovremennye problemy diagnostiki i lecheniia. Meditsinskii sovet. 2013; 3: 25–8. [in Russian]
________________________________________________
1. Yamaya M, Azuma A, Takizawa H et al. Macrolide effects on the prevention of COPD exacerbations. Eur Respir J 2012; 40: 485–94.
2. Min J, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators of Inflammation. 2012: Mediators Inflamm 2012: 649570. Published online 2012 June 6. DOI: 10.1155/2012/649570
3. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Intern J of COPD 2008; 3 (3): 331–50.
4. Luk'ianov S. V. Klinicheskaia farmakologiia makrolidov. Consilium Medicum. 2004; 6 (10): 769–73. [in Russian]
5. Mammen MJ, Sethi S. Macrolide therapy for the prevention of acute exacerbations in chronic obstructive pulmonary disease. Pol Arch Med Wewn 2012; 122: 54–9.
6. Luk'ianov S.V. Makrolidy v terapii vnebol'nichnykh infektsii dykhatel'nykh putei. Consilium Medicum. Respiratory organs diseases. (Suppl.). 2005; 1: 3–7. [in Russian]
7. Amsden G. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55 (1): 10–21.
8. Blasi F, Damato S, Cosentini R et al. Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax 2002; 57: 672–6.
9. Muto C, Liu P, Chiba K et al. Pharmacokinetic-pharmacodynamic analysis of azithromycin extended release in Japanese patients with common respiratory tract infectious disease. J Antimicrob Chemother 2011; 66: 165–74.
10. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global Strategy for Diagnosis, Management and Prevention of COPD. 2016: 111.
11. Kim N, Leeper KV Jr. Epidemiology of chronic bronchitis and acute infective exacerbations of chronic bronchitis. Semin Respir Crit Care Med 2000; 21 (2): 73–8.
12. Rosell A, Monso E, Soler N et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005; 165: 891–7.
13. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. ERJ 2007; 29: 1224–38.
14. Bach PB, Brown C, Gelfand SE et al. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001; 134: 600–20.
15. McCrory DC, Brown C, Gelfand SE et al. Management of acute exacerbations of COPD. A summary and appraisal of published evidence. Chest 2001; 119: 1190–209.
16. Allegra L, Blasi F, de Bernardi B et al. Antibiotic treatment and baseline severity or disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study. Pulm Pharmacol Therapeut 2001; 14: 149–55.
17. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005; 127: 2231–6.
18. Wilson R. Treatment of COPD exacerbations: antibiotics. Eur Respir Rev 2005; 14: 32–8.
19. Miravitlles M, D'Urzo A, Singh D, Koblizek V. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respir Res 2016; 17 (1): 112.
20. Contopoulos-Ioannidis DJ, Ioannidis JPA, Chew P, Law J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 2001; 48: 691–703.
21. Schouenborg P, Gerdes N, Rasmussen HH et al. Azithromycin versus Pivampicillin in the treatment of acute exacerbations of chronic bronchitis: a single-blind, double-dummy, multicentre study. J Inter Med Res 2000; 28: 101–10.
22. Dvoretskii L.I. Azitromitsin v lechenii infektsii dykhatel'nykh putei. Pozitsii sokhraniaiutsia. RMZh. 2004; 2: 83–7. [in Russian]
23. Uteshev D.B., Krylov I.A., Buiuklinskaia O.V. Azitromitsin: respiratornaia spetsifika i unikal'nost'. Lechebnoe delo. 2008; 1: 15–8. [in Russian]
24. Moiseev S.V. Azitromitsin v lechenii vnebol'nichnoi pnevmonii. Klin. farmakologiia i terapiia. 2006: 15 (2). [in Russian]
25. Fomina I.P., Ushkalova E.A. Primenenie azitromitsina dlia lecheniia vnebol'nichnykh pnevmonii u vzroslykh i detei. Farmateka. 2002; 11: 3-4. [in Russian]
26. Sinopal'nikov A.I., Zaitsev A.A. Azitromtsin: stupenchataia terapiia gospitalizirovannykh bol'nykh vnebol'nichnoi pnevmoniei (kliniko-ekonomicheskie sopostavleniia). Consilium Medicum. 2011; 13 (11): 10–4. [in Russian]
27. Asadi L, Sligl W, Eurich D. Macrolide-Based Regimens and Mortality in Hospitalized Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Clin Infect Dis 2012; 55 (3): 371–80.
28. Vnebol'nichnaia pnevmoniia u vzroslykh: prakticheskie rekomendatsii po diagnostike, lecheniiu i profilaktike. Posobie dlia vrachei. M., 2010: 54. [in Russian]
29. Klinicheskie rekomendatsii po diagnostike, lecheniiu i profilaktike tiazheloi vnebol'nichnoi pnevmonii u vzroslykh. Consilium Medicum. 2015; 17 (3): 8–37. [in Russian]
30. Shmelev E.I. Ostryi bronkhit. Atmosfera. Pul'monologiia i allergologiia. 2004; 3: 3–7. [in Russian]
31. Leshchenko I.V. Ostryi bronkhit: sovremennye problemy diagnostiki i lecheniia. Meditsinskii sovet. 2013; 3: 25–8. [in Russian]
Авторы
Н.А.Кароли, А.П.Ребров*
ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И.Разумовского» Минздрава России. 410012, Россия, Саратов, ул. Б. Казачья, д. 112
*andreyrebrov@yandex.ru
ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И.Разумовского» Минздрава России. 410012, Россия, Саратов, ул. Б. Казачья, д. 112
*andreyrebrov@yandex.ru
________________________________________________
N.A.Karoli, A.P.Rebrov*
Saratov State Medical University. 410012, Russian Federation, Saratov, ul. B. Kazach'ia, d. 112
*andreyrebrov@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.